Clinic Appointment 044-7102 6600, +91-7667999725 ( 9am - 5pm)

Development of Broadly Neutralising Monoclonal Antibody Mediated Prevention and Treatment Strategy by Assessing their Effectiveness in Neutralising HIV-1 Subtype C Circulating in India Across Different Regions and Distinct Risk Groups

Principal Investigators
Dr. K. G. Murugavel
Funding Agency
India Alliance Wellcome DBT
Translational Health Science and Technology Institute (THSTI), National Institute For Research In Reproductive and Child Health (NIRRH)


To assess the effectiveness of broadly neutralizing monoclonal antibodies in preventing and treating HIV-1 subtype C, which is commonly found in different regions and diverse risk groups in India. This assessment aims to develop a strategy that utilises these antibodies to effectively neutralise the virus and provide prevention and treatment options.


Integrated disease management approaches are increasingly promoted as a means to improve effectiveness and efficiency of healthcare for chronic diseases such as HIV/AIDS. Novel anti-HIV broadly neutralising monoclonal antibodies (bNAbs) hold promise in the prevention and treatment of HIV-1 infection. Hence, to develop an effective bnAbs based preventive and therapeutic solution for HIV, it becomes critical to assess people living with HIV (PLHIV) categorized into dissect risk groups, ethnicity with and without comorbidities. Through our proposed study, we aim to assess the potential of lead bnAbs as a product for prevention and therapy in the context of Indian subtype C viruses.